The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a wide range of neurological manifestations in patients. While respiratory disease is the predominant clinical presentation, neurological complications are increasingly being recognized. These include encephalopathy, encephalitis, Guillain-Barré syndrome, acute cerebrovascular disease, and anosmia and ageusia. The neurological manifestations are likely due to both direct viral infection and the body's immune response. Careful clinical, diagnostic, and epidemiological studies are needed to define the burden and mechanisms of neurological disease associated with SARS-CoV-2. Health-care planners and policymakers must prepare for the potential large number of neurological patients and their associated health, social, and economic costs.The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a wide range of neurological manifestations in patients. While respiratory disease is the predominant clinical presentation, neurological complications are increasingly being recognized. These include encephalopathy, encephalitis, Guillain-Barré syndrome, acute cerebrovascular disease, and anosmia and ageusia. The neurological manifestations are likely due to both direct viral infection and the body's immune response. Careful clinical, diagnostic, and epidemiological studies are needed to define the burden and mechanisms of neurological disease associated with SARS-CoV-2. Health-care planners and policymakers must prepare for the potential large number of neurological patients and their associated health, social, and economic costs.